

Press release

Parliament SANT Committee vote takes the high road on medicines security in Critical Medicines Act Report

16 December, Brussels, Belgium

The Parliament's SANT Committee report is a confident step forward for a robust Critical Medicines Act that will deliver on European open strategic autonomy and address the economic root causes of medicine shortages.

The members of the Public health Committee voiced strong support for:

- **The security of medicine supply in both medicine public procurement and** national pricing and reimbursement measures, to tackle the economic root cause of medicines shortages. Unlike other industrial goods, critical medicines are subject to cost-containment policies that force their prices down even when there are shortages of medicine or there is too much industrial consolidation.
- **Robust financial support** via a Critical Medicines Security Fund in the upcoming EU budget (MFF) and a new fit for purpose state aid guidance - diverse from SGEI - to support upgrades or reshoring for innovative production processes to embrace the digital and environmental transition and boost competitiveness of the off-patent medicine sector.
- **European solidarity** across Member States so that medicines go to patients instead of wasteful stockpiles. Countries like Germany and France have introduced large national stockpiling mandates that undermine the supply of medicines to countries like Poland, Netherlands, Sweden, Denmark, Finland, and Hungary.

In anticipation of the final European Parliament vote, we look forward to supporting this legislation targeting one of the key strategic sectors for the European Union. Medicines for Europe Director General, Adrian van den Hoven said: "The European Parliament has demonstrated that it has truly learned the lessons from Covid-19 by adopting clear policies to strengthen critical medicines supplies and to reduce medicine shortages. This is the way forward for EU health security."

Resource hub

- [Position paper on the Critical Medicines Act](#)
- [Factsheet on demand side measures](#)
- [National competences on mandatory security of supply criteria in procurement and pricing & reimbursement under the Critical Medicines Act](#)
- [Factsheet on stockpiling measures](#)
- [Factsheet on funding](#)

Medicines for Europe

Medicines for Europe represents the generic, biosimilar and value added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members directly employ 190,000 people at over 400 manufacturing and 126 R&D sites in Europe and invest up to 17% of their turnover in R&D investment. Medicines for Europe member companies across Europe are both increasing access to medicines and driving improved health outcomes. They play a key role in creating sustainable European healthcare systems by continuing to provide high quality, effective generic medicines, whilst also innovating to create new biosimilar medicines and bringing to market value added medicines, which deliver better health outcomes, greater efficiency and/or improved safety in the hospital setting for patients. For more information, please follow us at www.medicinesforeurope.com and on [LinkedIn](#) and X [@medicinesforEU](#).